Get startedLog in
    Picture of Nxera Pharma Co logo

    4565 — Nxera Pharma Co Cashflow Statement

    0.000.00%
    jp flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Nxera Pharma Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:YuhoYuhoYuhoYuhoYuho
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line4331,078-10,680-4,662-14,950
    Depreciation
    Non-Cash Items6,7113,5651,841-7927,910
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-1,3273,9641,088-6,2486
    Change in Accounts Receivable
    Change in Inventories
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities7,0959,952-5,273-7,718-2,668
    Capital Expenditures-201-303-851-1,537-625
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items4791,346-62,940-3,2266,055
    Acquisition of Business
    Sale of Business
    Sale/Maturity of Investment
    Change in Net Investments
    Other Investing Cash Flow
    Cash from Investing Activities2781,043-63,791-4,7635,430
    Financing Cash Flow Items-191-4,681-27-2-4,500
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities11,123-4,88748,329-6,854-16,028
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash20,0796,470-17,492-16,797-11,904